Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
June 16 2022 - 7:30AM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing nutritional cognitive
behavioral therapy (nCBT) to address the root causes of
cardiometabolic diseases, today announced that Kevin Appelbaum,
Co-Founder and CEO, will participate in the Commercializing
Prescription Digital Therapeutics panel at the Cowen 7th Annual
FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m.
ET.
The live panel will be available to registered participants in
the conference. To listen to the live panel, please contact your
Cowen representative.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220616005176/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024